Data temporarily unavailable
Unable to load analysis for « - » for now. Try again in a few moments.

Investlytic score: 1/5 criteria met.
- ❌ Price trend failed
- ❌ Growth failed
- ✅ Debt passed
- ❌ P/E failed
- ❌ Correction failed
Price trend
Overall trend (8 years): insufficient progression (less than x1.5).
Price change 2020 → 2021: -62.45%
Price change 2021 → 2022: -62.34%
Price change 2022 → 2023: -64.37%
Price change 2023 → 2024: -51.29%
Price change 2024 → 2025: -17.22%
Price change 2025 → 2026: -11.20%
Price change 2026 (year to date): -9.76%
Financial growth
Revenue CAGR (8 years): N/A
Earnings CAGR (8 years): N/A
Growth status: insufficient data or negative trend.
Debt
Debt-to-equity ratio: 0.01
Debt/equity < 0.5 (maximum threshold).
P/E (Price/Earnings)
P/E ratio: -1.20
P/E > 25.0 (maximum threshold).
Correction (6 months)
Current correction: 38.33% from the high over 6 months.
Excessive correction (> 20.0%).
Criteria of the Investlytic model
- / 5Free with the Investlytic logo. Paste this line into your page: options.
<script src="https://investlytic.co/encart.js" data-symbole="PMVP" data-lang="en"></script>Price trend
Price & trend
Interactive chart →💰 Dividend
Dividend ranking →⚖️ Comparison with the market
All stocks →| Stock | P/E | Dette/FP | Revenue growth | Rating |
|---|---|---|---|---|
| PMV Pharmaceuticals, Inc. | – | 0.01 | – | 🔒 |
| Klea Holding | 18.1 | 0.20 | +5.2 % | – |
| Euroapi S.A. | – | 0.08 | −1.3 % | – |
| DocCheck AG | 11.3 | 0.10 | +8.9 % | – |
| Coherus Oncology, Inc. | – | 0.66 | +26.9 % | – |
Data from the Investlytic screener. The rating of the stock being viewed is reserved for members.
Detailed analysis · Price trend
-
Revenues & profits
Revenue and net income
Financial indicators
Annual financial statements
| Fiscal year | Revenue | Net income | Net margin | EPS | Revenue growth |
|---|
PEA and practical information
Rule applied: the French PEA accepts shares of companies headquartered in the European Union or the European Economic Area and subject to corporate income tax; ADRs and tax-exempt property companies (SIIC) are excluded. The institution holding the PEA confirms eligibility.
Frequently asked questions about PMV Pharmaceuticals, Inc.
What is the PMV Pharmaceuticals, Inc. share price?
Latest recorded price: 1.27 USD on 13/11/2026, for a market cap of 67.7 m USD.
Is PMV Pharmaceuticals, Inc. stock eligible for the French PEA?
No: the company is headquartered outside the European Union and the European Economic Area (ISIN US69353Y1038).
How many employees does PMV Pharmaceuticals, Inc. have?
47 full-time employees according to the latest published profile.
Who runs PMV Pharmaceuticals, Inc.?
David H. Mack is the company's chief executive.